Search hospitals > Pennsylvania > Pittsburgh
West Penn Hospital
Claim this profilePittsburgh, Pennsylvania 15224
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
Conducts research for Breast Cancer
270 reported clinical trials
23 medical researchers
Summary
West Penn Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Ovarian Cancer, Adenocarcinoma, Lung Cancer, Breast Cancer and other specialties. West Penn Hospital is involved with conducting 270 clinical trials across 421 conditions. There are 23 research doctors associated with this hospital, such as Thomas Krivak, Gene G. Finley, Sarah Crafton, and Nathan Bahary, MD, PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Ovarian Cancer
Global LeaderStage IV
Stage III
BRCA1 positive
Top PIs
Thomas KrivakWest Penn Hospital5 years of reported clinical research
Expert in Ovarian Cancer
Studies Ovarian Tumors
14 reported clinical trials
36 drugs studied
Gene G. FinleyAllegheny General Hospital9 years of reported clinical research
Studies Lung Cancer
Studies Colorectal Cancer
12 reported clinical trials
41 drugs studied
Sarah CraftonWest Penn Hospital4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
12 reported clinical trials
21 drugs studied
Nathan Bahary, MD, PhDGSK Investigational Site4 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
10 reported clinical trials
28 drugs studied
Clinical Trials running at West Penn Hospital
Ovarian Cancer
Breast Cancer
Bladder Carcinoma
Non-Small Cell Lung Cancer
Bladder Cancer
Fallopian Tube Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Renal Cell Carcinoma
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
Heated Chemotherapy + Niraparib
for Ovarian Cancer
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC (Arm A) will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (Arm B) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per institutional standard (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 2-3 cycles) for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing until progression or 36 months (if no evidence of disease).
Recruiting2 awards Phase 3
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at West Penn Hospital?
West Penn Hospital is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Cancer, Ovarian Cancer, Adenocarcinoma, Lung Cancer, Breast Cancer and other specialties. West Penn Hospital is involved with conducting 270 clinical trials across 421 conditions. There are 23 research doctors associated with this hospital, such as Thomas Krivak, Gene G. Finley, Sarah Crafton, and Nathan Bahary, MD, PhD.